Navigation Links
'Intrabody' can mop up mutant protein in Huntington's disease model
Date:5/25/2008

Scientists have created a tool for mopping up the clumps of mutant protein that drive neurodegeneration in Huntington's disease. Emory University researchers engineered a virus to make an intracellular antibody or "intrabody" against huntingtin, the protein whose mutant forms poison the brain cells of people with Huntington's.

Injecting the virus into the brains of mice that make mutant huntingtin improves their ability to move their limbs, although it does not prolong their lives.

The results will be published online and are scheduled for publication in the May/June issue of the Journal of Cell Biology.

Although other researchers have shown that various intrabodies can protect cells from mutant huntingtin, the Emory team was the first to examine the effects of an intrabody in living mice, says senior author Xiao-Jiang Li, PhD, professor of human genetics at Emory University School of Medicine.

Delivering the intrabody to brain tissues in people would be a formidable challenge, because it would require some form of gene therapy. However, it may be possible to use information about the intrabody's structure to find drugs that mimic its effects, Li says.

Huntington's affects about 30,000 people in the United States and usually begins in young- to mid-adulthood with the slow destruction of brain cells, leading to involuntary movements, cognitive impairment and sometimes depression or paranoia. Another 150,000 people are believed to have mutations that cause the disease, but have not begun to show clinical symptoms. The disease is fatal and currently there is no way to slow its development, although some medications can alleviate symptoms.

Disease-causing mutations involve a lengthening of part of the gene for huntingtin, so that it repeats three letters (CAG) of the genetic code dozens of times. Mutant proteins have a region consisting of the same amino acid (glutamine) many times, called poly-glutamine, which
'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. What is the more suitable for early detection of low abundant lamivudine-resistant mutants?
2. FSU researchers mutant proteins could lead to new treatment for heart disease
3. Mutant gene causes epilepsy, intellectual disability in women
4. Effect of mutant p53 stability on tumorigenesis and drug design
5. Draining away brains toxic protein to stop Alzheimers
6. Penn study finds pro-death proteins required to regulate healthy immune function
7. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
8. Emory researchers identify signaling protein for multiple myeloma
9. Human C-reactive protein regulates myeloma tumor cell growth and survival
10. Lowering Blood Protein Wont Help Kidney Patients
11. Blood protein detects lung cancer, even at earliest stage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... Today the Centers for Disease Control and Prevention (CDC) ... the week was designed to highlight the importance of ... of taking additional steps to keep you and your ... of December, January and beyond. ,, "It,s easy to ... topic of both seasonal and swine flu," said Dr. ...
(Date:12/6/2009)... The University HealthSystem Consortium (UHC) recognized ... achievements in UHC,s Supply Chain Optimization Program. The ... modeling best practices in supply chain program participation. ... The winners were determined using 2008 data and ... participation and use of UHC resources. ,, Characteristics ...
(Date:12/6/2009)... targeting growth factor, researchers say , , SUNDAY, Dec. ... cells from the main tumor to other parts of ... as TGFb, which may prove a promising target for ... say. , Previous studies have shown that TGFb (transforming ... In this new study, a team from Cancer Research ...
(Date:12/6/2009)... Blood clotting, or coagulation, is an important process ... is injured. Sometimes, however, clots form on the ... do not dissolve naturally, a potentially life-threatening situation ... Annual Meeting of the American Society of Hematology ... aspirin and heparin with the hope of preventing ...
(Date:12/5/2009)... in a phase 1/2 clinical trial that it ... patients newly diagnosed with multiple myeloma, a cancer of ... Dana-Farber Cancer Institute. , Partial responses or better were ... the drug combination in the multi-center study, with 74 ... the phase 2 population, reports Paul G. Richardson, MD, ...
Breaking Medicine News(10 mins):Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 2Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 3Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Breast Cancer's Spread Now Better Understood 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2
... babies develop a fever high enough or abrupt enough ... to the emergency room, where their workup frequently includes ... meningitis. Now, in the largest study to date, researchers ... is probably not necessary in well-appearing children who have ...
... HAMILTON, Bermuda, Jan. 6 Warner Chilcott Limited (Nasdaq: ... signed an agreement with Dong-A PharmTech Co. Ltd., based ... product, a phosphodiesterase type 5 (PDE5) inhibitor for the ... Dong-A has successfully completed Phase 2 studies of ...
... Study found both physical function and quality of life improved ... of its kind finds that deep brain stimulation improves both ... patients with Parkinson,s disease. , Deep brain stimulation (DBS) performed ... some risks, including one death, according to a study in ...
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), ... that it plans to present from 8:30 a.m. to 9:00 ... J.P. Morgan Healthcare Conference in San Francisco. , The presentation ... web cast, which may be accessed by visiting http://investors.gentiva.com/events.cfm ...
... , ... Tampa, Fla. (Vocus) January 6, 2009 -- Whether you commit to your ... pets this year by bringing them in for regular check ups. Regular ... lead to a loved one,s life saved and less costly medical bills for ...
... the Centers for Disease Control and Prevention have produced the ... in sheep and human illness. , Dr. Edward Breitschwerdt, professor ... and NC State colleague Dr. Ricardo Maggi isolated the bacterium ... B. melophagi is such a newly discovered member ...
Other Medicine News:Health News:Most babies with uncomplicated febrile seizures can avoid spinal tap 2Health News:Most babies with uncomplicated febrile seizures can avoid spinal tap 3Health News:Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment 2Health News:Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment 3Health News:Deep Brain Stimulation Helps Those With Advanced Parkinson's 2Health News:Deep Brain Stimulation Helps Those With Advanced Parkinson's 3Health News:Gentiva(R) Health Services to Present January 13 at J.P. Morgan Healthcare Conference in San Francisco 2Health News:Gentiva(R) Health Services to Present January 13 at J.P. Morgan Healthcare Conference in San Francisco 3Health News:Early Detection Saves Pets 2Health News:Early Detection Saves Pets 3Health News:NC State researchers find new bartonella species that infects humans 2
(Date:12/4/2009)... highlighted a new report published by the ... that identifies 97 new drugs and vaccines in development for ... that the 97 products in development include 23 vaccines and ... or awaiting approval by the U.S. Food and Drug Administration ...
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), a ... chemical threats, announced today that the Company is ... of Valortim® in an inhalation anthrax model in ... data are being presented during an oral session ...
(Date:12/4/2009)... HOUSTON, Dec. 4 OrthoAccel Technologies, Inc., developers ... an acceleration device to enhance orthodontics, announced the ... by PennWell Corporation , a leader in ... dentistry. The course focuses on patient views ...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Cape tulips pretty but pests in pastures 9592 1Cape tulips pretty but pests in pastures 9592 2Derma Sciences Reports Second Quarter 2009 Results 54614 1Derma Sciences Reports Second Quarter 2009 Results 54614 2Derma Sciences Reports Second Quarter 2009 Results 54614 3Derma Sciences Reports Second Quarter 2009 Results 54614 4Derma Sciences Reports Second Quarter 2009 Results 54614 5Derma Sciences Reports Second Quarter 2009 Results 54614 6Derma Sciences Reports Second Quarter 2009 Results 54614 7Derma Sciences Reports Second Quarter 2009 Results 54614 8Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 13586 1Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 13586 2
... Stem Cell Sciences From University of Cambridge ... - ("Stem Cell Sciences", "SCS", "the Company"), ... STEM, ASX: STC), a company focused on the commercialisation ... paper describing a technique,for reprogramming adult mammalian cells into ...
... Research Develops Innovative ... ... the devastation,that cancer brings to families, workplaces and communities, and ... may be familiar with the CHRISTUS Stehlin Foundation for,Cancer Research, ...
Other Medicine Technology:Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 2Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 3Local Research Foundation Achieves Milestone in Fight Against Cancer 2Local Research Foundation Achieves Milestone in Fight Against Cancer 3
... of Alcon Acrylic, Chiron/Iolab LI-41 and Pharmacia & ... taller and thinner, maximizing the surface area around ... during loading and insertion, and makes it easy ... lens optic. The special direct-acting jaws release the ...
... / Ker Accuref K 9001 ... LCD color monitor. 3 step ... 2.3 mm Minimum pupil diameter ... adjuster. Auto start function. Kerato-Peripheral ...
... offers accuracy, speed, ease of use, ... is an Auto Refractor/Keratometer with both ... elevation, automatic alignment, focusing, printing, high-speed ... other features that have made the ...
Neomycin and Polymyxin B Sulfates and Hydrocortisone ophthalmic suspension is a sterile antimicrobial and anti-inflammatory suspension for ophthalmic use....
Medicine Products: